BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2026-08-07. BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. The firm is focused on its two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company also has a preclinical-stage product candidate, BH-501284, that leverages a novel chemical scaffold to selectively target and modulate activated KRAS. The firm is also advancing multiple discovery-stage efforts focused on validated and emerging new oncology targets.